Iodinated Contrast Media or CO₂: Safety and Renal Protection in Frail Patients
Iodinated contrast media safety and CO₂ angiography in frail patients
Iodinated contrast media safety depends on the patient’s clinical profile, renal function, the volume administered, and the type of procedure. This in-depth article is intended for vascular surgeons, interventional radiologists, healthcare management teams, and physicians who need to assess an angiographic examination in elderly patients or in people with chronic kidney disease, diabetes, heart failure, or previous contrast reactions.
In at-risk cases, CO₂ angiography can significantly reduce iodine exposure during vascular procedures below the diaphragm. The choice is neither automatic nor suitable for every vascular territory: it requires appropriate clinical indication, knowledge of contraindications, and a standardized protocol.
What determines the safety of iodinated contrast media?
Modern iodinated contrast media are generally safe, but they may cause adverse events in selected patients. The main renal risk is now described by distinguishing between contrast-associated AKI, meaning a worsening of renal function after the examination without necessarily demonstrating a causal relationship, and contrast-induced AKI, when iodinated contrast is considered the determining factor.
The historical term “contrast-induced nephropathy,” or CIN, is therefore used with caution. After a procedure, creatinine may also increase due to hypotension, sepsis, blood loss, nephrotoxic medications, or the underlying acute illness itself. This distinction is important for correctly interpreting risk and avoiding the automatic attribution of every renal injury to contrast media.
Which elderly or frail patients are at greater risk?
The most important predictive factor is renal function measured using the estimated glomerular filtration rate, or eGFR. An eGFR below 30 ml/min/1.73 m², especially in the presence of ongoing AKI, identifies a group in which intravascular iodine administration requires particularly careful assessment. An eGFR between 30 and 44 may require additional precautions when other risk factors are present.
Advanced age, diabetes, dehydration, heart failure, hypotension, anemia, the use of potentially nephrotoxic medications, and previous episodes of AKI increase vulnerability. Reduced muscle mass is also common in elderly patients; for this reason, creatinine alone may underestimate renal impairment and should be interpreted within the overall clinical context.
Before a complex procedure, the team should check up-to-date creatinine and eGFR values, hydration status, blood pressure, comorbidities, medications, and the expected contrast volume. In high-risk patients, involving a nephrologist, anesthesiologist, or referring physician may be appropriate according to the local hospital pathway.
What volume of iodine is considered safe?
There is no universal threshold that applies to every patient. Risk depends on volume, concentration, and total iodine dose, as well as on eGFR and hemodynamic stability. For this reason, the volume should be kept as low as possible while still maintaining adequate diagnostic image quality.
Ratios between contrast volume and renal function have been proposed in the literature and in clinical protocols, but they should not be regarded as absolute limits. A practical approach is to plan the maximum reasonable volume before the examination, avoid unnecessary repeated injections, and reassess the benefit of each acquisition.
Some observational studies have associated a contrast/eGFR ratio above approximately 1.0–1.5 with an increased risk of AKI in specific procedures, but the threshold varies depending on the population, route of administration, and complexity of the intervention. These values should therefore guide planning rather than replace clinical judgment.
Recommendations from ESUR and the American College of Radiology emphasize the importance of identifying at-risk patients, using the minimum diagnostic dose, and ensuring appropriate hydration when indicated. Hydration should be individualized: in patients with heart failure, excessive fluid administration may be harmful.
When can CO₂ angiography offer an advantage?
CO₂ is a gaseous contrast agent primarily used for vascular imaging below the diaphragm. It contains no iodine and is rapidly eliminated through the lungs. In patients with CKD, meaning chronic kidney disease, or with a high risk of AKI, it may allow iodinated contrast to be reduced or partially avoided.
The most practical benefit is a reduction in the renal iodine burden, not the promise of eliminating every complication. CO₂ can be used in peripheral angiography, lower-limb revascularization, arteriovenous fistulas for hemodialysis, and, in experienced centers using appropriate protocols, in selected aortic procedures such as EVAR or FEVAR.
Image quality depends on the vascular territory, patient positioning, movement, acquisition technique, and the experience of the clinical team. In some procedures, CO₂ may not adequately visualize every anatomical detail; a hybrid approach using a reduced amount of iodine may therefore be necessary instead of a CO₂-only strategy.
CO₂ or iodinated contrast: which option is safer?
The answer depends on the anatomy and the patient’s clinical condition. Iodinated contrast provides high image quality and is essential or preferable in many applications; however, in patients with severely reduced renal function, documented allergy, or a high risk of AKI, a contrast-sparing strategy with CO₂ can reduce iodine exposure.
CO₂ should not be used for arterial angiography above the diaphragm, such as coronary or cerebral angiography, because the gas may cause neurological or cardiac complications. Specific assessment is also required in the presence of right-to-left cardiac shunts, severe pulmonary hypertension, significant respiratory insufficiency, or other conditions listed in the device instructions for use and local protocols.
Manual, non-standardized administration may increase workflow variability. An automatic digital injector, such as the Angiodroid CO₂ Injector, allows injection parameters, repeatability, and traceability to be controlled, with dedicated consumables and team training. Technology does not replace clinical expertise, but it can help make the process more predictable.
How can the risk of AKI be reduced during an angiographic procedure?
Prevention begins with patient selection and the definition of a contrast target. When possible, dehydration and hypotension should be corrected, non-essential nephrotoxic medications should be avoided according to medical assessment, and the imaging technique with the best balance between information obtained and administered dose should be selected.
In frail patients, it can be useful to agree in advance on a CO₂-first, contrast-sparing, or CO₂-only strategy, defining when iodine should be used as a supplement. After the procedure, clinical and renal function monitoring should be proportionate to the patient’s risk and the complexity of the intervention.
An effective hospital pathway measures indicators such as average iodine volume per procedure, percentage of CO₂-first cases, changes in creatinine, AKI at 48–72 hours, length of stay, and readmissions. These data help healthcare management teams assess the actual benefit without relying solely on operators’ impressions.
What do recent studies show?
Available evidence includes observational studies, real-world series, and clinical trials focusing on high-risk vascular populations. Overall, they show that the use of CO₂ can reduce iodinated contrast volume while maintaining adequate technical effectiveness in selected procedures, particularly below the diaphragm.
However, studies do not demonstrate that CO₂ is superior in every scenario or that it completely eliminates renal risk. The quality of evidence is heterogeneous, and many outcomes depend on the experience of the treating center. Decisions should therefore integrate guidelines, indications for use, anatomy, eGFR, and the expertise of the clinical team.
Clinical trials and real-world registries, including the KID Trial and multicenter case series on CO₂ angiography, are helping to better define renal outcomes, safety, and clinical applicability. For an up-to-date assessment, indexed publications, ESUR and ACR guidelines, vascular scientific society recommendations, and local outcome data should all be considered.
How can a hospital start a CO₂-first pathway?
Adoption should begin with an assessment of the case mix: number of patients with CKD, peripheral procedures performed, average iodine volume, and frequency of AKI. The center can then develop a multidisciplinary protocol defining inclusion criteria, contraindications, image management, and escalation to iodine when required.
Practical training is essential. Workshops, live cases, and mentorship allow interventional radiologists and vascular surgeons to learn the behavior of CO₂, optimize image acquisition, and recognize the limitations of the technique. A structured program reduces the learning curve more effectively than introducing the device in isolation.
To receive a preliminary assessment of the pathway, technical requirements, and training program, request an Angiodroid consultation. The team can help the center define a contrast-sparing pathway aligned with its patient population, workflow, and renal safety objectives.
Frequently Asked Questions
Is iodinated contrast media always dangerous for elderly patients?
No. Age alone does not make iodinated contrast contraindicated. Risk increases mainly in the presence of AKI, severely reduced eGFR, dehydration, hypotension, heart failure, or other vulnerability factors.
What is the maximum permitted volume of iodinated contrast?
There is no universal maximum volume. The limit should be individualized according to eGFR, iodine dose, the procedure, and hemodynamic conditions; contrast/eGFR ratios such as 1.0–1.5 are planning references described in some studies, not absolute thresholds.
Can CO₂ completely replace iodinated contrast?
A CO₂-only strategy is possible in some vascular procedures below the diaphragm, but not in every patient or vascular territory. In many cases, the most appropriate approach is CO₂-first or hybrid, with a small amount of iodine used when needed to complete imaging.
Is CO₂ angiography indicated for cerebral or coronary vessels?
No. CO₂ is not indicated for arterial angiography above the diaphragm, including cerebral and coronary territories. Its use requires compliance with the indications for use, contraindications, and the center’s protocols.
What should healthcare management assess before purchasing the system?
It should consider the patient population treated, compatible procedures, expected reduction in iodine use, training, consumables, workflow integration, and outcome indicators. A pilot project measuring contrast volume, AKI, length of stay, and readmissions provides a more robust assessment of clinical and economic value.
